{"nctId":"NCT00368069","briefTitle":"A Study to Look at the Efficacy and Safety of Keppra速 Extended Release Formulation - XR","startDateStruct":{"date":"2006-08"},"conditions":["Epilepsy"],"count":158,"armGroups":[{"label":"Keppra速 XR","type":"EXPERIMENTAL","interventionNames":["Drug: Keppra速 extended release formulation - XR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Keppra速 extended release formulation - XR","otherNames":["Levetiracetam XR"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of refractory epilepsy\n* Patients must be receiving a stable dose of 1 - 3 concomitant Anti-Epileptic Drugs (AED)\n* Female patients without childbearing potential. Female patients with childbearing potential are eligible if they use a medically accepted non-hormonal contraceptive method\n\nExclusion Criteria:\n\n* Seizures occurring in clusters\n* Status epilepticus within 3 months of Visit 1\n* History of non-epileptic seizures\n* Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients\n* Pregnant or lactating women. Any woman with childbearing potential who is not using a medically accepted, non-hormonal method of birth control","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Partial Onset Seizure (POS) Frequency Per Week - Intention-To-Treat (ITT) Population","description":"Number of POS over the treatment period standardized to 1 week period.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.912","spread":"0.053"},{"groupId":"OG001","value":"1.067","spread":"0.052"}]}]}]},{"type":"SECONDARY","title":"POS Seizure Frequency Per Week Over Baseline and Treatment Period","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null},{"groupId":"OG001","value":"2.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null},{"groupId":"OG001","value":"1.36","spread":null}]}]}]},{"type":"SECONDARY","title":"All (Type I+II+III) Seizures Frequency Per Week","description":"Number of All type Seizures over the treatment period standardized to 1 week period (Type I -Partial Onset Seizures, Type II - Generalized Seizures, Type III - Unclassified Epileptic Seizures)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.928","spread":"0.053"},{"groupId":"OG001","value":"1.086","spread":"0.052"}]}]}]},{"type":"SECONDARY","title":"50% Response in Weekly POS Frequency","description":"A subject is considered as a 50% responder in POS if he/she has a \\>= 50% decrease from Baseline in the POS frequency/week over Treatment period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Response in Weekly POS Frequency (Categorized Into 6 Categories According to Reduction) Over the Treatment Period of 12 Weeks","description":"The response is classified according to the percent reduction from baseline in the POS frequency per week over the Treatment Period of 12 weeks duration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Partial Onset Seizure (POS) Frequency Per Week - Per Protocol (PP) Population","description":"Number of POS over the treatment period standardized to 1 week period","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.914","spread":"0.049"},{"groupId":"OG001","value":"1.119","spread":"0.048"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":77},"commonTop":["Headache","Influenza","Nasopharyngitis","Somnolence","Nausea"]}}}